Shares of Mangoceuticals Inc (NASDAQ:MGRX), which sells men's health products under the MangoRx brand, are trading sharply higher Friday afternoon after the company reported momentum for its $99-per-month injectable testosterone replacement therapy (TRT) program.

Here’s what investors need to know.

• Mangoceuticals shares are powering higher. Why is MGRX stock surging?

TRT Sales Surge 336%

Since launching in mid-December, month-over-month sales for the injectable TRT program have climbed 336%, while customer acquisition costs have fallen 54%, the company said in an update.

Management expects TRT to be the primary growth driver as MangoRx expands both injectable and oral options, including its PRIME capsule, powered by Kyzatrex.

Telehealth Platform Targets Growing TRT Market

Chief executive Jacob Cohen said the early demand highlights the value of the firm's telehealth-first approach to men's hormone care and its push to improve marketing efficiency.

MangoRx operates an online platform offering prescription treatments for erectile dysfunction, hair growth, hormone replacement and weight management.

The company on Friday cited industry research valuing the global TRT market at $2.11 billion to $2.2 billion in 2025, with expected compound annual growth of 3.9% in the coming years, supported by an aging population and wider diagnosis of low testosterone.

MGRX Shares Skyrocket Friday

MGRX Price Action: Mangoceuticals shares were up 42.12% at $0.51 at the time of publication on Friday. The stock is near its 52-week low of $0.34, according to Benzinga Pro data.

Image: Shutterstock

• No comments yet. Be the first to comment!